Progesterone Receptor Negative Recruiting Phase 1 Trials for Eribulin (DB08871)

IndicationStatusPhase
DBCOND0038639 (Progesterone Receptor Negative)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03579472M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast CancerTreatment